Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?

J Hepatol. 2008 Jun;48(6):892-4. doi: 10.1016/j.jhep.2008.03.010. Epub 2008 Apr 1.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • DNA, Viral / blood
  • Drug Monitoring / methods*
  • Drug Resistance, Viral / genetics*
  • Genetic Predisposition to Disease / genetics
  • Guanine / analogs & derivatives
  • Guanine / therapeutic use
  • Hepatitis B / blood
  • Hepatitis B / drug therapy*
  • Hepatitis B virus / genetics
  • Humans
  • Lamivudine / therapeutic use
  • Mutation / genetics
  • Nucleosides / therapeutic use*
  • Nucleotides / therapeutic use*
  • Phenotype

Substances

  • Antiviral Agents
  • DNA, Viral
  • Nucleosides
  • Nucleotides
  • Lamivudine
  • entecavir
  • Guanine